BioSpace News Archive

AVITA Medical Limited (Company) (ASX:AVH, NASDAQ:RCEL) is pleased to announce that the Federal Court of Australia (Court) has today approved orders to convene a meeting of the Company’s shareholders to consider and, if thought fit, approve the proposed scheme of arrangement (Scheme) under which AVITA Therapeutics, Inc.

Simcere Pharmaceutical Group, a leading pharmaceutical company in China, and Primary Peptides Inc., a privately held biotech company in Canada, today announced a collaboration and exclusive license agreement to develop and commercialize an innovative product for the treatment of stroke.

In an analysis accepted for presentation at the American Association of Clinical Endocrinologists (AACE) Annual Scientific & Clinical Congress, physicians cite psychological well-being and ability to function in social situations as most impacted by the disease

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.

Independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the Phase 2b NASH study

Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced financial results and operational highlights for the first quarter ended March 31, 2020.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced that the Company will present at Bank of America Securities 2020 Health Care Conference, Wednesday, May 13, 2020 at 11:40 a.m. ET.

Anchiano Therapeutics Ltd., a preclinical biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies, reported financial results for its first quarter ended March 31, 2020.

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced its financial results and operational highlights for the first quarter ended March 31, 2020.

Sientra, Inc., a diversified medical aesthetics company, announced its financial results for the first quarter ended March 31, 2020.